Group 1 - The core point of the article is that Qianyuan Pharmaceutical announced a board meeting to discuss the proposal for engaging in financing leasing business [1] - For the year 2024, the revenue composition of Qianyuan Pharmaceutical is as follows: 96.68% from pharmaceutical manufacturing, 1.93% from DNA gene preservation and prenatal environment testing services, 0.79% from health food, 0.51% from other businesses, and 0.1% from commercial activities [1] - As of the report date, Qianyuan Pharmaceutical has a market capitalization of 2.7 billion yuan [1] Group 2 - A significant breakthrough has been recognized for a new drug in China, which has been acknowledged by both Chinese and American officials for its breakthrough efficacy, generating excitement at the World Lung Cancer Conference [1]

证券代码：300254 证券简称：仟源医药 公告编号：2025-063 山西仟源医药集团股份有限公司 第五届董事会第三十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山西仟源医药集团股份有限公司（以下简称"公司"）于 2025 年 9 月 12 日 以邮件方式发出第五届董事会第三十三次会议通知及议案，2025 年 9 月 15 日以 通讯表决的方式召开本次会议。本次会议由董事长黄乐群先生主持，应出席董事 9 名，实际出席董事 9 名。出席会议人员对本次会议的召集、召开方式无异议。 本次会议的召集、召开符合《公司法》、《公司章程》和《董事会议事规则》的有 关规定。 二、董事会会议审议情况 出席本次会议的全体董事对本次会议的议案进行了认真审议，并以投票表决 方式审议通过《关于公司开展融资租赁业务的议案》。 经审议：我们认为公司本次办理融资租赁售后回租业务，能够盘活公司固定 资产，拓宽融资渠道，优化融资结构，为生产经营提供长期资金支持。本次开展 融资租赁售后回租业务，不影响公司相关资产的正常使用，不会对公司的生产经 营产生 ...

一、融资租赁业务概述 为盘活现有资产、拓宽融资渠道、满足日常经营的资金需求，山西仟源医药 集团股份有限公司（以下简称"公司"）将开展融资租赁售后回租业务，公司使 用部分固定资产采用售后回租的方式与向平安点创国际融资租赁有限公司（以下 简称"平安点创"）申请融资额不超过 5,000 万元，期限 2 年半。应平安点创要 求，由控股子公司浙江仟源海力生制药有限公司及公司总裁赵群先生为公司在平 安点创的上述融资租赁业务提供连带保证责任。融资租赁事项的相关租赁利率、 租金及支付方式等具体内容以实际签订的协议为准。 公司已于2025年9月15日召开第五届董事会第三十三次会议，审议通过了《关 于公司开展融资租赁业务的议案》。根据《深圳证券交易所创业板股票上市规则》、 《公司章程》等相关规定，本次审议事项属于公司董事会决策权限，无需提交公 司股东会审议。同时，董事会授权总裁或其指派的相关人员在批准的额度内办理 公司融资租赁业务的一切事宜。 公司与平安点创无关联关系，本次融资租赁售后回租事项不构成关联交易， 亦不构成《上市公司重大资产重组管理办法》中规定的重大资产重组。 证券代码：300254 证券简称：仟源医药 公告编号：2 ...

Group 1 - The core point of the article is that Zhao Qun, a major shareholder and the president of Qianyuan Pharmaceutical, increased his stake in the company, becoming the largest single shareholder [1] - Zhao Qun acquired 2,079,900 shares through centralized bidding from September 11 to 12, 2025, representing 0.84% of the total share capital [1] - After the acquisition, Zhao Qun holds a total of 15,781,792 shares, which is 6.36% of the company [1] Group 2 - Zhao Qun's action was supported by his concerted action partner, Huang Lequn, who holds 5,465,060 shares, accounting for 2.20% of the total shares [1] - Together, Zhao Qun and Huang Lequn own a combined total of 8.56% of the company [1] - Following this change, the company still has no actual controller or controlling shareholder [1]

Core Viewpoint - QianYuan Pharmaceutical (300254.SZ) announced that its major shareholder, Zhao Qun, increased his stake in the company, becoming the largest single shareholder with 6.36% of the total share capital [1] Shareholding Changes - Zhao Qun acquired an additional 15,781,792 shares through the Shenzhen Stock Exchange from September 11 to September 12, 2025 [1] - Zhao Qun's action partner, Huang Lequn, holds 5,465,060 shares, representing 2.20% of the total share capital [1] - Together, Zhao Qun and Huang Lequn own a total of 21,246,852 shares, accounting for 8.56% of the total share capital [1] Shareholder Structure - The change in the largest single shareholder does not affect the company's compliance with listing conditions [1] - Zhao Qun and Huang Lequn remain the largest shareholders, and the company does not have a controlling shareholder or actual controller [1]

证券代码：300254 证券简称：仟源医药 公告编号：2025-062 山西仟源医药集团股份有限公司 关于持股5%以上股东增持公司股份的比例触及1%的整数倍 暨公司单一第一大股东变更的公告 公司持股 5%以上股东、董事、总裁赵群先生保证向本公司提供的信息内容 真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示：持股5%以上股东、董事、总裁赵群先生于2025年9月11日-2025 年9月12日通过深圳证券交易所证券交易系统以集中竞价交易方式增持了公司股 份，增持完成后，持有公司股份15,781,792股，占公司总股本的6.36%，成为公 司单一第一大股东。同时，赵群先生的一致行动人黄乐群先生持股5,465,060股， 占公司总股本的2.20%，赵群先生及其一致行动人黄乐群先生合计持股21,246,852 股，占公司总股本的8.56%。本次单一第一大股东变更不会导致公司股权分布不 符合上市条件，公司第一大股东仍为赵群先生及其一致行动人黄乐群先生，公司 仍无实际控制人和控股股东，不会导致公司实际控制人及控 ...

Core Viewpoint - On September 7, Suzhou Bank disclosed plans for share buybacks by its directors and senior management, while 20 A-share listed companies announced share reductions by their executives and shareholders [1][2]. Group 1: Share Buybacks - Suzhou Bank's directors, supervisors, and senior management plan to buy back shares worth no less than 4.2 million yuan [2]. Group 2: Share Reductions - Multiple directors and executives from Zhuhai Co. plan to reduce their shareholdings [2]. - Specific shareholders of Yingyang Intelligent, including directors, plan to reduce their stakes [2]. - Nantong Yuxiang intends to reduce its holdings by up to 0.66% in Hongde Co. [2]. - Shareholders of Xiangshan Co. plan to reduce their holdings by no more than 3% [2]. - Five directors and executives of Qianyuan Pharmaceutical plan to reduce their holdings by up to 0.1718% [2]. - Controlling shareholders and executives of Xingshuai Co. plan to reduce their holdings by no more than 2.71% [2]. - Vice President Liu Bin of Rongke Technology plans to reduce his holdings by no more than 63,000 shares [2]. - Shareholder Lei Yan Investment of Green Alliance Technology plans to reduce its holdings by no more than 1.63% [2]. - Controlling shareholders and actual controllers of Runhe Materials plan to reduce their holdings by no more than 3% [2]. - Sunshine Life intends to reduce its holdings in Huakang Clean by no more than 3% [2]. - Shareholder Ruan Jilin of Baida Precision plans to reduce his holdings by no more than 0.99% [2]. - Controlling shareholders and actual controllers of Jusa Long plan to reduce their holdings by no more than 3% [2]. - Controlling shareholder Yulide Group of Youlide plans to reduce its holdings by no more than 2% [2]. - Shareholders of Lutianhua plan to collectively reduce their holdings by no more than 3% [2]. - Dazhi Yintai intends to reduce its holdings in Wushang Group by no more than 22.4971 million shares [2]. - Shareholder Shunfeng Investment of Kejie Intelligent plans to reduce its holdings by no more than 3% [2]. - Shareholders of Shangwei Co. plan to reduce their holdings by no more than 3% [2]. - Jiangshan Co. intends to reduce its holdings by no more than 3% [2]. - Water Planning Investment plans to reduce its holdings in Deepwater Planning by no more than 3% [2]. - Controlling shareholder and actual controller Xie Qian of Zhuoyi Information plans to reduce his holdings by no more than 3% [2].

Group 1 - QianYuan Pharmaceutical announced that several executives plan to reduce their holdings in the company by a total of approximately 290,000 shares, which represents 0.1165% of the total share capital [1] - The company's revenue composition for the year 2024 is as follows: pharmaceutical manufacturing accounts for 96.68%, DNA gene preservation and prenatal environment testing services account for 1.93%, health food accounts for 0.79%, other businesses account for 0.51%, and commercial activities account for 0.1% [1] - As of the report, QianYuan Pharmaceutical has a market capitalization of 2.7 billion yuan [2]

Group 1 - The company Shanxi Qianyuan Pharmaceutical Group Co., Ltd. announced a pre-disclosure of share reduction by several directors and senior management [1] - The total shares planned to be reduced by the five individuals amount to no more than 426,600 shares, representing 0.1718% of the company's total share capital [1] - The individuals involved in the reduction include Yu Junxian, Gu Baoping, Yu Yingmin, He Yanjie, and Luo Kairui, with specific shareholdings and planned reductions detailed [1][2] Group 2 - The reasons for the share reduction include tax payments related to equity incentives and personal funding needs [2] - The shares to be reduced are sourced from various holdings, including pre-IPO shares, capital reserve conversions, and equity incentive grants [2] - The reduction price will be determined based on market conditions at the time of the sale, indicating some uncertainty in the execution of the plan [3] Group 3 - The share reduction plan does not violate any relevant laws or regulations and will not lead to changes in the company's control or governance structure [3] - The company will continue to monitor the progress of the share reduction plan and fulfill its information disclosure obligations as required [3]

Core Viewpoint - QianYuan Pharmaceutical (300254.SZ) announced that several executives plan to reduce their holdings in the company within three months after a 15 trading day period from the announcement date [1] Summary by Relevant Categories Shareholding Reduction - Executive Yu Junxian plans to reduce holdings by up to 289,200 shares, accounting for 0.1165% of the total share capital of the company [1] - Executive Gu Baoping plans to reduce holdings by up to 43,700 shares, accounting for 0.0176% of the total share capital of the company [1] - Executive Yu Yingmin plans to reduce holdings by up to 43,700 shares, accounting for 0.0176% of the total share capital of the company [1] - Executive He Yanjie plans to reduce holdings by up to 25,000 shares, accounting for 0.0101% of the total share capital of the company [1] - Executive Luo Kairui plans to reduce holdings by up to 25,000 shares, accounting for 0.0101% of the total share capital of the company [1]